(P-1117) An Open-label Phase 1 Study in Healthy Adult Male Participants to Investigate the Absorption, Metabolism, and Excretion of [¹⁴C]-Rifaquizinone Following a Single Intravenous Administration

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

MA

Mohamed Al-Ibrahim, MB ChB

Pharmaron Clinical Pharmacology Center (CPC)
Baltimore, Maryland, United States
BK

Bradly Keck, PhD

Pharmaron Clinical Pharmacology Center (CPC)
Baltimore, Maryland, United States
MC

Marie Croft, PhD

Pharmaron ABS, Inc.
Germantown, Maryland, United States
SE

Stephen English, BS

Pharmaron ABS, Inc.
Germantown, Maryland, United States
EB

Eleanor Barton, Master

Pharmaron UK Ltd.
Rushden, England, United Kingdom
LK

Loewe Kasprenski, MBA

Pharmaron Clinical Pharmacology Center (CPC)
Baltimore, Maryland, United States
Huan Wang, PhD (she/her/hers)

Director of pharmacology and toxicology
TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China (People's Republic)
CA

Changlin Ai, Master of Medicine

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China
GG

Guozhu Geng, MD

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China
Jing Chen, Master of Science (she/her/hers)

VP Clinical Operation
TenNor Therapeutics （Suzhou） Ltd
Suzhou, Jiangsu, China (People's Republic)

Zhenkun Ma, PhD (he/him/his)

CEO
TenNor Therapeutics
Suzhou Industrial Park, Jiangsu, China (People's Republic)